
Valbenazine, a vesicular monoamine transporter 2 inhibitor, has shown promise in relieving chorea associated with Huntington's disease (HD), according to a recent phase III trial. The study involved 128 individuals with genetically confirmed HD and chorea, who were treated with valbenazine or a placebo for 12 weeks. The group receiving valbenazine experienced significant reductions in their chorea scores compared to the placebo group, as measured by the Unified HD Rating Scale Total Maximal Chorea. Valbenazine, which is already FDA-approved for tardive dyskinesia, demonstrated good tolerability and safety.
Like
Save
Share